Skip to content

Intratumor RNA interference of cell cycle genes slows down tumor progression.

By Dharmapuri, S.; Peruzzi, D.; Marra, E.; Palombo, F.; Bett, A. J.; Bartz, S. R.; Yong, M.; Ciliberto, G.; La Monica, N.; Buser, C. A.; et al
From Gene Therapy (2011), 18(7), 727-733. Language: English, Database: CAPLUS, DOI:10.1038/gt.2011.27

Small interfering RNAs (siRNAs) are emerging as promising therapeutic tools. However, the widespread clin. application of such mols. as modulators of gene expression is still dependent on several aspects that limit their bioavailability. One of the most promising strategies to overcome the barriers faced by gene silencing mols. involves the use of lipid-based nanoparticles (LNPs) and viral vectors, such as adenoviruses (Ads). The primary obstacle for translating gene silencing technol. from an effective research tool into a feasible therapeutic strategy remains its efficient delivery to the targeted cell type in vivo. In this study, we tested the capability of LNPs and Ad to transduce and treat locally tumors in vivo. Efficient knockdown of a surrogate reporter (luciferase) and therapeutic target genes such as the kinesin spindle protein (KIF11) and polo-like kinase 1 were obsd. Most importantly, this activity led to a cell cycle block as a consequence and slowed down tumor progression in tumor-bearing animals. Our data indicate that it is possible to achieve tumor transduction with si/short hairpin RNAs and further improve the delivery strategy that likely in the future will lead to the ideal non-viral particle for targeted cancer gene silencing.

More info on PubMed.gov

IRBM IN THE NEWS

PRESS RELEASES

EVENTS

Back To Top